The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. We provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today, The Institute of Cancer Research (ICR) leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment. Under the leadership of our Chief Executive, Professor Paul Workman FMedSci, the ICR is ranked as the UK’s leading academic research centre. Together with our partner The Royal Marsden, we are rated in the top four cancer centres globally.The ICR is committed to attracting, developing and retaining the best minds in the world to join us in our mission – to make the discoveries that defeat cancer.
The Cancer Research UK Cancer Therapeutics Unit, within the Division of Cancer Therapeutics, is a multidisciplinary 'bench to bedside' centre, comprising around 160 staff dedicated to the discovery and development of novel therapeutics for the treatment of cancer. The Cancer Therapeutics Unit’s exciting goal is to discover high quality small molecule drug candidates and to progress these to clinical trial. All the scientific disciplines are in place to make this possible, including medicinal chemistry, biology, drug metabolism and clinical specialists who focus on new molecular targets emerging from human genome and ground breaking cell biology research.
In addition to the recently advertised postdoctoral protein crystallography position available in Dr Rob van Montfort’s Hit Discovery and Structural Design Team within the CTU (Ref. 1624336, closing date January 27th 2017) a second postdoctoral protein crystallography position is now available in Dr van Montfort’s team (Ref. 1627317). The successful candidate will establish the successful _expression_, purification and characterisation of one of our early stage targets, using contemporary _expression_ systems and purification methods available within the Team. The Post-doc will establish the in-house crystallisation and structure determination for this exciting early stage target in CTU’s drug discovery portfolio and subsequently carry out the structural determination of protein-ligand complexes. In addition, the post-holder is expected to initiate the development of biochemical and biophysical assays development to monitor protein function. The successful candidate will be an integral member of a multidisciplinary project team and will interact closely with the biologists, computational chemists, medicinal chemists and structural biologists and will therefore be expected to work across the two sites in Chelsea, London and Sutton, Surrey. Applicants must have a PhD in a biological or physical science, and experience in macromolecular crystallography (to include protein biochemistry, protein crystallisation, & protein crystallography). Expertise in assay development and biophysical techniques would be advantageous. The starting salary for this position will be up to £35,538p.a. inclusive (based on previous experience). Appointment will be on a fixed-term contract for 1 year and benefits from a contributory defined benefit pension scheme and generous leave entitlement.
We are also seeking two highly motivated Higher Scientific Officers with experience in protein _expression_ and purification to join Dr van Montfort’s team (Ref. 1627310). The postholders will be involved in establishing and carrying out the protein _expression_, purification, and characterisation of cancer targets to enable biochemical screening, high-throughput protein crystallography and Structure-Based Drug Design projects at the Unit. Applicants must be educated to degree level in a biological science and will ideally have an MSc or PhD in a relevant subject. Experience and demonstrable skills in molecular biology, protein _expression_ in E.coli and protein purification are essential. Experience in protein _expression_ in insect and/or mammalian cells and or biophysical techniques such as SPR, DSF and ITC is highly desirable.The starting salary for the two positions will be in the range Point 1 £32,145 - Point 4 £36,080 p.a. according to experience and the posts are offered initially on a fixed term contract 2 year contract.
Closing date for the three positions (Ref. 1627317 and Ref. 1627310) is February 17th 2017. Informal enquiries to email@example.com - but applications must be submitted on-line (www.icr.ac.uk).
The Institute of Cancer Research: Royal Cancer Hospital, a charitable Company Limited by Guarantee, Registered in England under Company No. 534147 with its Registered Office at 123 Old Brompton Road, London SW7 3RP.
This e-mail message is confidential and for use by the addressee only. If the message is received by anyone other than the addressee, please return the message to the sender by replying to it and then delete the message from your computer and network.